Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.70 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.70 |
| ▸ | DHFR | P00374 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12904188 | 1.00 | SLC6A3 (0.70) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL10101580 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL12550069 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL20850913 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL1462581 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL16700055 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL6099068 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL14453321 | 0.85 | SLC6A3 (0.78) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| Hydrochloric Acid SCHEMBL2988020 | 0.84 | SLC6A3 (0.76) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 | |
| SCHEMBL14453323 | 0.82 | SLC6A3 (0.74) | SLC6A3SLC6A2SLC6A4DHFRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723589-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | THE GENERAL HOSPITAL CORPORATION (US) | 2023-08-15 | — | — | US | disclosed |
| US-20130310422-A1 | REVERSAL OF GENERAL ANESTHESIA BY ADMINISTRATION OF METHYLPHENIDATE, AMPHETAMINE, MODAFINIL, AMANTADINE, AND/OR CAFFEINE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-11-21 | — | — | US | disclosed |
| US-20130109719-A1 | METHOD OF TREATING ATTENTION DEFICIT DISORDERS WITH D-THREO METHYLPHENIDATE | ZEITLIN ANDREW L (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723589-B2 | Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine | ACHE, ADORA2A, COMT | SLC6A3 188/4885SLC6A2 112/4885SLC6A4 393/4885 |
| US-20130109719-A1 | METHOD OF TREATING ATTENTION DEFICIT DISORDERS WITH D-THREO METHYLPHENIDATE | SLC6A3, COMT, SLC6A4 | SLC6A3 1/4885SLC6A2 4/4885SLC6A4 3/4885 |
| US-20130310422-A1 | REVERSAL OF GENERAL ANESTHESIA BY ADMINISTRATION OF METHYLPHENIDATE, AMPHETAMINE, MODAFINIL, AMANTADINE, AND/OR CAFFEINE | ACHE, ADORA2A, ADORA1 | SLC6A3 259/4885SLC6A2 149/4885SLC6A4 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.